In renal cell carcinoma (RCC), REN-mediated activation of the RAS—especially the Ang II/AT1R axis—within the tumor microenvironment has been shown to drive pro-tumorigenic processes such as angiogenesis, inflammation, and metastasis, as well as immune suppression (36). This evidence concerns the gene REN and neoplasm.